BOx-II: Brain Oxygenation-II

Sponsor
Valerie Chock, M.D., M.S. Epi (Other)
Overall Status
Recruiting
CT.gov ID
NCT05171881
Collaborator
Washington University School of Medicine (Other), Cerebral Palsy Alliance (Other)
100
5
1
19.8
20
1

Study Details

Study Description

Brief Summary

The Brain Oxygenation-II study (BOx-II) is a phase-II, multicenter, single-arm clinical trial evaluating interventions based on near-infrared spectroscopy (NIRS) monitoring of cerebral oxygen saturation in extremely premature infants. Enrolled infants will follow a treatment guideline to maintain cerebral oxygen saturation in a target range within the first 72 hours of life. The primary outcomes will include interventions used to maintain cerebral saturation in target range, rates of cerebral hypoxia and systemic hypoxia, and a composite of death or severe brain injury detected on term-equivalent magnetic resonance imaging.

Condition or Disease Intervention/Treatment Phase
  • Other: Intervention for cerebral hypoxia
Phase 2

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
Single arm interventional study to maintain cerebral oxygen saturation in targeted rangeSingle arm interventional study to maintain cerebral oxygen saturation in targeted range
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Brain Oxygenation in Extremely Preterm Infants-II
Actual Study Start Date :
Apr 7, 2022
Anticipated Primary Completion Date :
Apr 1, 2023
Anticipated Study Completion Date :
Dec 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Interventional Arm

All infants will undergo non-invasive NIRS monitoring of cerebral oxygen saturation and will have algorithm-driven clinical interventions to maintain cerebral saturation within target range during the first 72 hours of life.

Other: Intervention for cerebral hypoxia
For cerebral oxygen saturation measures below target range (cerebral hypoxia), a treatment algorithm with the following potential clinical interventions will be applied: fluid resuscitation, initiation of vasopressor/inotrope medication, change in mechanical ventilation or respiratory support, adjustment of fractional inspired oxygen, transfusion of red blood cells, acquisition of echocardiogram or cranial ultrasound.

Outcome Measures

Primary Outcome Measures

  1. Frequency of interventions used to address cerebral hypoxia [From birth until 72 hours of life]

    Frequency of specific interventions chosen to address cerebral hypoxia

Secondary Outcome Measures

  1. Rates of cerebral hypoxia and systemic hypoxia [From birth until 72 hours of life]

    Rates of cerebral hypoxia as detected by near-infrared spectroscopy (NIRS) monitoring of cerebral oxygen saturation and systemic hypoxia as detected by conventional pulse oximetry monitoring of systemic oxygen saturation

  2. Rates of death or severe brain injury [36-42 weeks corrected gestational age]

    Rates of death or severe brain injury (including intraventricular hemorrhage, white matter injury, cystic periventricular leukomalacia, cerebellar hemorrhage, post-hemorrhagic ventricular dilation, or cerebral atrophy) detected on term-equivalent magnetic resonance imaging performed between 36 and 42 weeks corrected gestational age.

Other Outcome Measures

  1. Rates of other neonatal morbidities [Birth until hospital discharge, an average of 3 months]

    Rates of other neonatal morbidities including bronchopulmonary dysplasia, severe retinopathy of prematurity, and/or mortality before neonatal intensive care unit discharge

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A to 6 Hours
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Infants born with postmenstrual age less than 28 weeks

  • Signed informed consent

Exclusion Criteria:
  • Missing written parental informed consent

  • Decision not to conduct full intensive care support

  • No possibility to place cerebral NIRS oximeter within six hours after birth

  • Skin integrity insufficient to allow for sensor placement as deemed by a clinician

Contacts and Locations

Locations

Site City State Country Postal Code
1 Loma Linda University Loma Linda California United States 92350
2 Stanford University Palo Alto California United States 94304
3 Washington University in Saint Louis Saint Louis Missouri United States 63110
4 University of Texas- Southwestern Medical Center Dallas Texas United States 75390
5 University of Virginia Charlottesville Virginia United States 22903

Sponsors and Collaborators

  • Valerie Chock, M.D., M.S. Epi
  • Washington University School of Medicine
  • Cerebral Palsy Alliance

Investigators

  • Principal Investigator: Valerie Chock, MD, Stanford University
  • Principal Investigator: Zachary Vesoulis, MD, Washington University in Saint Louis

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Valerie Chock, M.D., M.S. Epi, Associate Professor of Pediatrics, Stanford University
ClinicalTrials.gov Identifier:
NCT05171881
Other Study ID Numbers:
  • 56759b
First Posted:
Dec 29, 2021
Last Update Posted:
May 11, 2022
Last Verified:
May 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 11, 2022